Generating significant returns and multiplying their money in the stock market remains a primary goal for most investors. However, high excess returns (alpha) are challenging to generate, let alone doubling money. For example, if someone took a bet on the overall economy and bought the broader market index, it would have taken around five to seven years for them to double the investments, as these indices usually take that much time, depending on the economic cycle and market trends. Such gains are never easy to replicate, but certain companies and sectors are better positioned for high growth due to strong fundamentals, innovation, or macroeconomic trends. Investors who can identify these stocks through research and understanding market cycles can generate extra returns. Moreover, specific stocks’ valuation and growth trajectory over the next few years must be precisely analysed to make good returns.

Over the last five years, the stock market has been highly dynamic, reflecting broader economic shifts, interest rate cycles, and technological advancements. While 2023 and 2024 were volatile because of concerns over inflation, the Federal Reserve policy, and geopolitical tensions, 2025 has been equally volatile, with the S&P 500 down 3% and the Nasdaq down around 8% (as of March 27). This volatility makes higher returns riskier.

Nevertheless, market analysts are still optimistic about gains in 2025. In an interview with CNBC on April 1, Chris Hyzy, Merrill and BofA Private Bank CIO, said he would use recent market weakness to increase positions and favour broad market exposure through equal-weighted S&P positions. He identifies financials and consumer discretionary stocks as particularly oversold and attractive. He also believes that certain areas, like software and cybersecurity, could lead the technology sector in share market gains in the coming months. Chris also suggested that while uncertainty may persist into the summer, markets will likely begin pricing in anticipated improvements in economic conditions and corporate earnings later in the year. According to his assessment, the job market remains stable and strong, which would mean a sharp economic downturn is unlikely. He expects the market to experience a “sawtooth bottom” rather than a sharp V-shaped recovery, suggesting that long-term opportunities remain despite persisting volatility.

Fundstrat’s head of research, Tom Lee, stated to CNBC on March 31 that market conditions indicate oversold status and potential bottom formation regardless of ongoing downward trends. Investors maintain their focus on government policies and tariff situations, and their economic impact. According to his estimates, the April 2 tariff updates should also clarify the future of policies and could potentially reduce selling pressure in the market. He also believes that as and when the Federal Reserve communicates further on interest rates, inflation, and other policies, it should provide more direction to investors.

In essence, opportunities could emerge in the near term, and investors should look for better entry points to create positions to generate more substantial returns. But stock selection also remains key. According to Goldman Sachs Asset Management’s March 24 report, Embracing a Broader Equity Landscape, while the technology sector remains a key driver of growth in 2025, the dominance of a few large U.S. tech companies appears to be waning. The authors highlighted that capital is beginning to diversify beyond the Magnificent 7, and many of today’s market leaders may not sustain their positions at the top. This evolving market dynamic presents new opportunities for active investors, particularly in smaller-cap equities, high-quality businesses outside the U.S., and differentiated long-term investment themes. As leadership broadens, they believe this shift could mark the beginning of a more favorable environment for stock selection across the global equity landscape.

In recent months, many analysts and fund managers have favored diversifying towards small- and mid-cap stocks; thus, this space should remain on investors’ radars. At the same time, investors should be aware of the risks involved in high-performing equities.

With those insights, let’s explore the 10 unstoppable stocks that could double your money.

Our Methodology

To identify the unstoppable stocks that could double investors’ money, we used online screeners to compile a list of U.S.-listed companies with a market capitalization exceeding $2 billion and with a greater than 20% return in the last one year. We then applied an additional criterion, considering only those stocks with an expected upside of around 100% or more. From the refined list, we took the top 10 stocks with the highest upside potential and ranked them in ascending order of respective upsides. Additionally, we provided insights into hedge fund sentiment surrounding these stocks, using data from Insider Monkey’s Q4 2024 database.

Note: All pricing data is as of market close on March 27, 2025. 1-year returns are calculated from March 27, 2024.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

10 Unstoppable Stocks That Could Double Your Money

10. Oklo Inc. (NYSE:OKLO)

1-Year Return: 114%

Upside Potential: 99%

Number of Hedge Fund Holders: 27

Oklo Inc. (NYSE:OKLO) is an advanced nuclear reactor company that commercialises small modular reactors (SMRs) for clean and reliable power generation. Company’s flagship product, the Aurora Powerhouse, is a compact fission power system designed to provide carbon-free, baseload energy for industrial, commercial, and microgrid applications.

Oklo is positioned to address power demand needs across multiple end markets, the largest being the data center, which is expected to constitute 30% of total demand growth between 2022 and 2030. The company signed some significant deals in 2024, the largest one was the corporate power agreement with Switch, a pure-play data center company, for 12 gigawatts (GW) of Aurora powerhouse projects through 2044, which brought customer backlog to over 14GW. It also signed an agreement for 500 MW of power with Equinix, another data center company. These deals highlight the company’s long-life reactors and nuclear waste recycling capabilities, positioning it firmly to capitalise on the growing global demand for sustainable and secure energy sources.

Following Oklo Inc.’s (NASDAQ:OKLO) Q4 results, a Craig-Hallum analyst reduced the price target slightly to $43 from $44 while keeping a Buy rating on the stock. The analyst noted that the company is building momentum in 2025. He also believes that progress is expected to increase as the company advances toward deploying its first Aurora Powerhouse at Idaho National Labs and expands its efforts in powering data centers.

Oklo Inc. (NASDAQ:OKLO) shares have risen around 114% over the last year.

9. Avidity Biosciences Inc. (NASDAQ:RNA)

1-Year Return: 32%

Upside Potential: 107%

Number of Hedge Fund Holders: 41

Avidity Biosciences Inc. (NASDAQ:RNA) is a clinical-stage biotech company developing a new type of RNA-based medicines called Antibody Oligonucleotide Conjugates (AOCs). These medicines are designed to deliver genetic treatments directly to the tissues affected by disease, helping target rare genetic conditions that currently have no effective treatments.

The company is trying to revolutionise the delivery of RNA therapeutics, and several of its therapies are under clinical trials. Leerink Partners analyst Joseph Schwartz recently reiterated a Buy rating on Avidity Biosciences Inc. (NASDAQ:RNA) with a $60 price target, citing promising clinical data from the company’s exon skipper candidate, del-zota, for Duchenne muscular dystrophy (DMD). The analyst pointed to encouraging results and believes these improvements could provide meaningful patient clinical benefits.

He also highlighted that Avidity is on track to submit a Biologics License Application (BLA) by the end of 2025, without requiring additional biopsies for new patients. The analyst stated that Avidity’s upcoming program represents their initial commercial entry, while internal activities like manufacturing, along with patient services and market access teams’ development, are already in motion. The small commercial potential of DMD for Avidity does not deter the analyst from seeing this program as essential groundwork for expanding the company’s muscular dystrophy medication development.